These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37851403)

  • 1. High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series.
    Westerkamp AC; Pereira RR; Huitema VR; Kouwert EAM; Matic M; van Schaik RHN; Punt N; Schoevers RA; Touw DJ
    J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):35-38. PubMed ID: 37851403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
    Johnson KA; Barry E; Lambert D; Fitzgerald M; McNicholas F; Kirley A; Gill M; Bellgrove MA; Hawi Z
    J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):655-64. PubMed ID: 24350812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR
    Adjei AL; Chaudhary I; Kollins SH; Padilla A
    Paediatr Drugs; 2020 Oct; 22(5):561-570. PubMed ID: 32776159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.
    Nemoda Z; Angyal N; Tarnok Z; Gadoros J; Sasvari-Szekely M
    Neuropharmacology; 2009 Dec; 57(7-8):731-3. PubMed ID: 19733552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder, with focus on high doses and relationship to carboxylesterase activity.
    Arvidsson M; Franck J; Ackehed G; Pettersson Bergstrand M; Ekström L; Rosenborg S; Dahl ML
    Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):492-500. PubMed ID: 35040257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
    Teuscher NS; Sikes CR; McMahen R; Engelking D
    J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?].
    Akyol Ardıç Ü; Ercan ES; Aygüneş D; Yüce D; Durak S; Kosova B
    Turk Psikiyatri Derg; 2017; 28(2):89-94. PubMed ID: 29192941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.
    Lyauk YK; Stage C; Bergmann TK; Ferrero-Milliani L; Bjerre D; Thomsen R; Dalhoff KP; Rasmussen HB; Jürgens G
    Clin Transl Sci; 2016 Dec; 9(6):337-345. PubMed ID: 27754602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Belchenko D; Lempa B
    Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder.
    Gomeni R; Komolova M; Incledon B; Faraone SV
    J Clin Psychopharmacol; 2020; 40(4):350-358. PubMed ID: 32590405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
    Zhu HJ; Appel DI; Peterson YK; Wang Z; Markowitz JS
    Toxicology; 2010 Apr; 270(2-3):59-65. PubMed ID: 20097249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.
    Braeckman R; Guenther S; Mickle TC; Barrett AC; Smith A; Oh C
    J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):288-295. PubMed ID: 35666231
    [No Abstract]   [Full Text] [Related]  

  • 18. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
    Xiao J; Shi J; Thompson BR; Smith DE; Zhang T; Zhu HJ
    J Pharm Sci; 2022 Sep; 111(9):2606-2613. PubMed ID: 35526575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
    Liu T; Gobburu JVS; Po MD; McLean A; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):181-191. PubMed ID: 30810347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
    Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
    BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.